Investigating the role of immune cell processes in coronary artery disease
Role of Mitophagy in Myeloid Cells During Coronary Atherosclerosis.
Centre Hospitalier Universitaire Dijon · NCT05708547
This study is trying to see if changes in immune cells can help us understand coronary artery disease better by comparing patients with and without atherosclerosis.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire Dijon (other) |
| Locations | 1 site (Dijon) |
| Trial ID | NCT05708547 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the role of mitophagy in myeloid cells during coronary atherosclerosis by comparing patients with atherosclerosis to those without. It will involve collecting blood and myocardial tissue samples from 50 patients scheduled for cardiac surgeries, divided into two groups based on their coronary health. The study seeks to identify a non-invasive marker for immune cell reprogramming associated with atherosclerosis, which could enhance understanding of the disease's progression. Participation will last for one month, and the study will be conducted at the Dijon Bourgogne University Hospital.
Who should consider this trial
Good fit: Ideal candidates include patients scheduled for cardiac bypass or valve surgery who meet specific health criteria related to coronary and peripheral artery conditions.
Not a fit: Patients with conditions that alter mitochondrial function or those under legal protection measures will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to the identification of new biomarkers for coronary atherosclerosis, improving early detection and treatment strategies.
How similar studies have performed: While the specific approach of this study is novel, similar studies have shown promise in understanding immune cell roles in atherosclerosis.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: - Person who provides oral consent Group 1: - Patient scheduled for cardiac bypass surgery (isolated procedure) with extracorporeal circulation Group 2: * Patient scheduled for valve ou ascending aorta surgery with extracorporeal circulation * No coronary lesion * No peripheral arterial disease (limbs, carotids, aortic aneurysm) Exclusion Criteria: * Person not affiliated with national health care system * Medication that alters mitochondrial function (Chloroquine, hydroxychloroquine, rapamycin, carbamazepine, resveratrol, sildenafil) * Person under a legal protection measure (curatorship, guardianship, tutorship) * Pregnant, parturient or breastfeeding women * Major unable to express consent * Minor
Where this trial is running
Dijon
- Chu Dijon Bourgogne — Dijon, France (RECRUITING)
Study contacts
- Study coordinator: Pierre-Alain BAHR
- Email: pierre-alain.bahr@chu-dijon.fr
- Phone: 03 80 29 30 21
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Coronary Atherosclerosis